Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Eli Lilly and Company and Purdue University are keeping their partnership alive beyond it’s previously expected years. In an ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the ...

Amazon.com, Nvidia, Tesla, and the rest of the Magnificent Seven stocks jump as the U.S. and China reach an agreement to ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

Tesla Shares in electric vehicle maker Tesla have climbed back to their highest point since February, amid investor optimism ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...